Sushentsev, Nikita http://orcid.org/0000-0003-4500-9714
McLean, Mary A.
Warren, Anne Y.
Brodie, Cara
Jones, Julia
Gallagher, Ferdia A.
Barrett, Tristan
Funding for this research was provided by:
Prostate Cancer UK (PA14-012)
Cancer Research UK (Grants C19212/A27150, C19212/A16628, C197/A29580, C197/A17242)
Article History
Received: 1 February 2022
Revised: 13 April 2022
Accepted: 23 May 2022
First Online: 22 June 2022
Declarations
:
: The scientific guarantor of this publication is Dr. Tristan Barrett.
: The authors of this manuscript declare relationships with the following companies: F.A.G. has research support from GE Healthcare, and grants from GlaxoSmithKline, and has consulted for AstraZeneca on behalf of the University of Cambridge. The remaining authors declare no conflict of interest.
: No complex statistical methods were necessary for this paper given the exploratory analyses used. The authors acknowledge the input of Dr. Oleg Blyuss of Queen Mary University of London who provided helpful guidance on the appropriate use of the Bland-Altman analysis.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained (National Research Ethics Service Committee East of England, Cambridge South, Research Ethics Committee number 16/EE/0205). This was a retrospective study of data acquired prospectively, with all patients providing written consent to participate in this study upon their recruitment between May 2018 and February 2020. Retrospective analysis presented in this manuscript was covered by the initial Institutional Review Board approval.
: Some study subjects or cohorts have been previously reported in Sushentsev N, McLean MA, Warren AY, et al (2022) Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer. <i>Nat Commun</i> 2022 131 13:1–12. ExternalRef removed
: • retrospective• observational• performed at one institution